[18F]UCB-2897 for Multi-System Atrophy

Invicro, New Haven, CT
Multi-System Atrophy+2 More Conditions[18F]UCB-2897 - Drug
Eligibility
18+
All Sexes

Study Summary

This trial will test the safety and effectiveness of a new imaging agent, [18F]UCB-2897, in people with Parkinson's disease or Multiple System Atrophy. The goal is to see if the agent can produce a specific signal in the brain related to alpha-synuclein, a protein involved in these diseases.

Eligible Conditions
  • Multi-System Atrophy
  • Parkinson's Disease
  • Healthy Subjects

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

1
18F-LY3950321 Whole Body Dosimetry
1
Terazosin
1
AAV2-GDNF gene therapy

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: [18F]UCB-2897 PET Imaging Visit

Day 1
Quantitative analysis of [18F]UCB-2897 brain PET scans
Screening, pre-injection, and at the completion of imaging
Safety Outcome Measures
[18F]UCB-2897 PET Imaging Visit
Whole-body Biodistribution Outcome Measures

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
18F-LY3950321 Whole Body Dosimetry
1
Terazosin
1
AAV2-GDNF gene therapy

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

[18F]UCB-2897
1 of 1

Experimental Treatment

14 Total Participants · 1 Treatment Group

Primary Treatment: [18F]UCB-2897 · No Placebo Group · Phase 1

[18F]UCB-2897
Drug
Experimental Group · 1 Intervention: [18F]UCB-2897 · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: [18f]ucb-2897 pet imaging visit

Who is running the clinical trial?

InvicroLead Sponsor
16 Previous Clinical Trials
398 Total Patients Enrolled
Joyce Gibbons, PA-CPrincipal InvestigatorSub-Investigator
Amy Knorr, MDPrincipal InvestigatorSub-Investigator
David Russell, MD, Ph.DPrincipal InvestigatorPrincipal Investigator

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

To what extent is the participant pool of this research project expanding?

"That is accurate. According to the information on clinicaltrials.gov, this medical trial was initially posted on January 31st 2022 and last modified on March 1st 2022. Currently, there are 14 patients needed across one single site for the study's completion." - Anonymous Online Contributor

Unverified Answer

Are there any current opportunities to join this experiment?

"According to the records hosted on clinicaltrials.gov, this trial is searching for participants; it was published at the beginning of January 2021 and underwent its most recent update in March 2022." - Anonymous Online Contributor

Unverified Answer

What are the potential hazards associated with administering [18F]UCB-2897?

"Due to the limited data available, [18F]UCB-2897 was assigned a score of 1 in terms of safety on our team's scale. This is because this trial only reaches Phase 1 status and there is restricted information confirming efficacy or security." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top